ARID1A and gastric cancer: Based on the findings mentioned earlier, a new study will evaluate the combination of oxaliplatin, simvastatin (HMG-CoA reductase inhibitor), and nivolumab (anti-PD-1) in patients with advanced GC/EC and ARID1A mutation; however, it is not currently recruiting participants [146].